Early diagnosis and treatment of steroid-induced diabetes mellitus in patients with rheumatoid arthritis and other connective tissue diseases

REFERENCES

• Guedes C, Dumont-Fischer D, Leichter-Nakache S, Boissier MC. Mortality in rheumatoid arthritis. Rev Rhum. 1999;66:492�8.
   Google Scholar
• del Rinccon I, Willams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737�45.
   Google Scholar
• Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001;13:345�51.
   Google Scholar
• Urowitz MB, Gladman DD, Tom BD, Iban� ez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol. 2008;35: 2152�8.
   Google Scholar
• Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late mani- festations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299�308.
   Google Scholar
• Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577�83.
   Google Scholar
• Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekik- awa A. Impaired glucose tolerance is a risk factor for cardio- vascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920�4.
   Google Scholar
• The DECODE Study Group (on behalf of the European Diabetes Epidemiology Group). Glucose tolerance and mortality: com- parison of WHO and American Diabetic Association diagnostic criteria. Lancet. 1999;354:617�21.
   Google Scholar
• Campbell IW. Nateglinide�current and future role in the treat- ment of patients with type 2 diabetes mellitus. Int J Clin Pract. 2005;59:1218�28.
   Google Scholar
• Tentolouris N, Voulgari C, Katsilambros N. A review of nate- glinide in the management of patients with type 2 diabetes. Vasc Health Risk Manag. 2007;3: 797�807.
   Google Scholar
• Goke B, Herrmann-Rinke C. The evolving role of alpha-gluco- sidase inhibitors. Diabetes/Metab Res Rev. 1998;14:S31�8.
   Google Scholar
• Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am. 1997;26:539�51.
   Google Scholar
• Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract. 2007;105:c54�7.
   Google Scholar
• Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Clevel Clin J Med. 2011;78:748�56.
   Google Scholar
• Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and the risk of cardiovascular dis- ease and hypertension in patients with impaired glucose toler- ance: the STOP-NIDDM trial. JAMA. 2003;290:486�94.
   Google Scholar
• Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900�8.
   Google Scholar
• WHO. Report of a WHO consultation: de?nition, diagnosis and classi?cation of diabetes mellitus and its complications. Part 1. Diagnosis and classi?cation of diabetes mellitus. Geneva: Department of Noncommunicable Disease Surveillance, World Health Organization; 1999.
   Google Scholar
• Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab. 2011;96:1789�96.
   Google Scholar
• Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in ?ve populations of Asian origin. Diabetologia. 2004;47:385�94.
   Google Scholar
• Ishida T. Steroid diabetes (in Japanese). Diabetes Frontier. 2007�8;18:332�5.
   Google Scholar
• Kondo Y, Ito S, Ogishima H, Sugihara M, Umeda N, Horikoshi M, et al. Early diagnosis of steroid diabetes using 1,5-anhydro-Dglycitol and good control for blood sugar. Presented at: 52nd Scientific Meeting of Japan College of Rheumatology; 2008 April 20–23; Sapporo, Japan. P3�440.
   Google Scholar
• Miwa S, Watada H, Ohmura C, Tanaka Y, Kawamori R. Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide. Endocr J. 2004;51: 393�8.
   Google Scholar
• Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes/Metab Res Rev. 2001;17: 467�73.
   Google Scholar
• Nakajima A, Doki K, Homma M, Sagae T, Saito R, Ito S, et al. Investigation of glucocorticoid-induced side effect in patients with autoimmune disease (in Japanese). Yakugai Zassi. 2009;129:445�50.
   Google Scholar
• Yanai H, Masui Y, Yoshikawa R, Kunimatsu J, Kaneko H. Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes. World J Diabetes (China). 2010;1: 99�100.
   Google Scholar
• Ito S. Steroid induced diabetes mellitus (in Japanese). In: Diagnosis and treatment of adverse effects of drugs/development of new drugs. Technical Information Institute. Tokyo; 2012. p. 443�4.
   Google Scholar